Phase I/II trial of pembrolizumab and AR signaling inhibitor +/- 225Ac-J591 for chemo-naive metastatic castration-resistant prostate cancer (mCRPC).
Abstract
TPS216
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Feb 20, 2022
- Source ID
- 10.1200/jco.2022.40.6_suppl.tps216
Entities
People
- Amie Patel
- Ana M. Molina
- Angela Tan
- Cora Sternberg
- David M. Nanus
- Himisha Beltran
- Jones Nauseef
- Joseph Osborne
- Karla V. Ballman
- Mahelia Bissassar
- Matthew Dallos
- Neil Harrison Bander
- Paraskevi Giannakakou
- Peter Gregos
- Scott T Tagawa
- Sharon Singh
Organizations
- Columbia University
- Dana–Farber Cancer Institute
- National Institutes of Health
- United States Department of Defense
- Weill Cornell Medicine